News for HLS Therapeutics Inc. (HLTRF)

Revenue: $14.1 million for Q3 2024.Adjusted EBITDA: $4.1 million for Q3 2024.Cash from Operations: $1.5 million for Q3 2024.Net Sales Growth in Canada: 9% incr

Nov 07, 2024 / 01:30PM GMTOperator Good morning and welcome to the Q3 fiscal '2024 financial results conference call for a HLS Therapeutics. At this point, I wo

HLS Therapeutics Inc (TSX:HLS) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $20.58 million, and the earn

Revenue: $14.5 million for Q2 2024.Adjusted EBITDA: $4.3 million for Q2 2024.Cash from Operations: $2.5 million for Q2 2024.Operating Expenses: Reduced by 13%

Aug 08, 2024 / 12:30PM GMTOperator Good morning, and welcome to the Q2 fiscal 2024 financial results conference call for HLS Therapeutics. On this morning's cal

Pacira director retains board seat despite shareholder dissent

Earnings call: Amarin reports Q2 2024 results, eyes global VASCEPA expansion

Buy Medexus Pharma (MEDXF) Market Cap: $34MM Price: $1.38 Price Target: $4+ Upside: 189%+ Summary Medexus Pharma (MEDXF) truly represents an asymmetric opportunity. The stock trades at 2x FCF and 5.2x EBITDA. Does the company have a lot of debt? No! Its net debt to EBITDA is currently 2.2x and will be 1.5x by the end of the year. Does the

Mar 14, 2024 / 12:30PM GMTOperator And good morning and good morning, and welcome to the Q4 and fiscal 2023 financial results conference call for HLS Therapeuti

HLS Therapeutics Inc. announced results from new REDUCE-IT analyses adding to the growing body of knowledge on the clinical impact of Vascepa . These new analyses show that among statin-treated...

Here's a long list of biopharmas exposed to SVB. Many of these deposits will be uninsured. Click here to see which companies may be affected.